Several people on the board present constant fearmongering here, and these fears are absurd. Israel has faced war and fought wars for many many years and it never stopped TEVA. Those saying to make it a US company are insane. That won't help the stock price. GROWTH will help the stock price. New successes will help the stock price. Replacing lost Copaxone revenues will eventually help the stock price.
I wonder about these same people - After Nine Eleven, did they call for all US banks to be moved overseas? Did they email the IR of Citi or whatever bank is in their portfolio asking them to move the company elsewhere? Afterall, US isn't safe... right? Irrational thought processes. Not every company has to be a US company.
This stock is the most under priced comapny in the market today in my humble opinion. I just don't get it, its like someone is just sitting on it almost seems like the treasury market in the US as we know the 1000 pound gorilla "the Fed" is sitting on the long end.... This is a coiled spring and some day we will bounce far.
The least they could do is let stockholders know that if something catastrophic happens in Isreal, they have the redundancies set up elsewhere to not affect company. All numbers say this should be a $50 stock, but here we are at 40. The cloud of being in Israel has to be lifted. Copaxone is not the problem with 2 more good years, so what else could it be??
All the analysts, and Teva itself, forecast peak sales for Copaxone in the year 2012. Why do you think that is?
Time to get with the program, teva's earnings will take a hit. Luckily for us, the multiple is already low, it's largely already been discounted, so when it does predictably happen, there won't be AS MUCH pain. And if there is upside surprise, we will benefit greatly.
There are NOT 2 more good years because BG12 has a pdufa date in December of this year. That is serious competition. THAT was always the threat, not the momentards or other generic rip offs.
Look at BG12's phase 3 trial. It went HEAD TO HEAD WITH COPAXONE.
IT TROUNCED COPAXONE!
The investors know this competition is on its way, so the 2 years without generics will not be smooth sailing. How can an investor in teva be so ignorant as to not recognize the correct risk factors and the correct strengths?